Interestingly, in a complementary approach where high-risk resected stage III or stage IV melanoma patients were immunized with pools of long peptides containing predicted neoantigens prioritized based solely on HLA-A or HLA-B predicted binding affinity, neoantigen-specific CD4+ T cell responses were seen in addition to CD8+ T cell responses, and 10% of immunizing peptides generated both CD4+ and CD8+ responses (Ott et al., 2017). Here, CD8A is linked to melanoma.